Aledort L M, Bohn R L
Mount Sinai School of Medicine, New York, NY 10029-6574, USA.
Blood Coagul Fibrinolysis. 1996 Mar;7 Suppl 1:S35-7.
Little is known about the ideal factor regimen for hemophiliacs nor how treatment should be administered. A prospective multicenter study evaluated different dosage regimens and defined orthopedic outcomes, based on factor consumption and a comparison of prophylaxis with on-demand therapy. Prophylaxis led to better outcomes, whether joints were initially normal or previously affected. Factor use was substantially more costly if prophylaxis was used, but a major reduction could be achieved if continuous infusion were feasible.
对于血友病患者的理想因子治疗方案以及治疗应如何实施，人们所知甚少。一项前瞻性多中心研究评估了不同的剂量方案，并根据因子消耗以及预防性治疗与按需治疗的比较来确定骨科治疗结果。无论关节最初是否正常或之前是否受累，预防性治疗都能带来更好的结果。如果采用预防性治疗，因子的使用成本会大幅增加，但如果可行连续输注，则可以大幅降低成本。
